Document:

EX-10.20

 Certain information in this document identified by brackets has been omitted because it is
both not material and would be competitively harmful if publicly disclosed. 
 Exhibit 10.20 

58.com Inc., Wuba Co., Ltd. 

And 
 58 Daojia Inc.,
Tianjin Wuba Daojia Life Service Co., Ltd. 
 BUSINESS COOPERATION AGREEMENT 

Party A1: 58.com Inc., a company incorporated and validly existing under the laws of the Cayman Islands 

Party A2: Wuba Co., Ltd., Beijing Wuba Information Technology Co., Ltd. and their affiliated companies (together with Party A1, collectively
“Party A”) 
 Party B1: 58 Daojia Inc., a company incorporated and validly existing under the laws of the British Virgin Islands 

Party B2: Tianjin Wuba Daojia Life Service Co., Ltd., Beijing Wuba Daojia Information Technology Co., Ltd. and their affiliated companies (together with Party
B1, collectively “Party B”) 
 To promote the development of the 58 Daojia business, Party A and Party B hereby entered into this Business
Cooperation Agreement on November 27, 2015 through friendly consultation (this “Agreement”) as follows: 
  

	 	1.	 Provide [***] resources to 58 Daojia 

Party A agrees to provide Party B with [***] on 58.com (58同城), ganji.com (赶集网) and their waps and apps owned by Party A. The specific [***] are as set forth in
Appendix 1. 
 If [***] of Party B is affected due to product upgrade on 58.com
(58同城) and ganji.com (赶集网) owned by
Party A, Party A and Party B shall conduct friendly consultation, and Party A shall provide [***]. 
 Party A agrees to grant Party B
the most favored nation treatment with respect to [***], i.e. if Party A invests in a third party and its proportion of equity or interest in such third party is equal to or below its proportion of equity or interest in Party B, [***] granted by
Party A to Party B shall not be inferior to that granted by Party A to the third party. 
  

	 	2.	 Brand Authorization 

Party A is applying for trademarks for many brands necessary for Party B to carry out Daojia business, such as “58 到家”、“58Daojia”、“到家速运”、“58 到家速运”、“58 到家懒人节”、“懒人节” (“Daojia Brands”). If the
Daojia Brands are approved to be registered trademarks by the Trademark Office, Party B shall have the right to choose to obtain the trademark rights in the form of [***], provided the validity of the registered trademarks shall not be affected.
Party A shall, at the choice and request of Party B, assign the trademark or grant a license to Party B for the use thereof [***] during the valid period of the trademarks, or assign the right to apply for the trademark to Party B (if the trademarks
have not been registered yet) without affecting the application for the registered trademarks. If the assignment or the right to apply for the registered trademark may affect the validity of the registered trademark or the right to apply for the
registered trademark, the way of licensing Party A to Party B for use thereof [***] during the valid period of the trademarks shall be adopted. If the method of transfer is adopted, the transfer price shall be at the minimum price permitted by
applicable laws and regulations, provided that such assignment will not incur material costs and expenses to Party B. In the future, with respect to other intangible assets and intellectual property which are related to the business carried out by
Party B but are not registered, Party A and Party B shall confirm the applicant through consultations. However, Party A shall, at the choice and request of Party B, transfer or license such intangible assets or intellectual property to Party B and
such transfer or license shall not incur any substantial cost to Party B. Party A will not transfer or license such intellectual property rights or application right to any third party other than Party B. 

 Scope of use of brands: resident service industry, internet information service, software
development, software technology service, development and construction of e-commerce platform, general cargo transportation, moving services, loading, unloading and moving, road cargo transportation agency,
maternal and child health management services, sports services, maternal and child care services, maternal and child health care services (excluding medical diagnosis), job intermediary services, labor outsourcing services, talent intermediary
services, labor and social security affairs agency services, public employment services, family services, housekeeping services, beauty services, hairdressing services, nail dressing services, luggage handling services, car cleaning services, pet
beauty services, property cleaning, maintenance, car beauty, labor outsourcing services, human resource outsourcing services, etc. 
 If
Party B wishes to use other derivative brands which are related to Party B’ business but are owned by Party A, it shall obtain additional authorization from Party A. 

All trademarks or brands authorized by Party A to Party B under this Article shall be the exclusive license to Party B for the entire valid
period of such trademarks and such license shall not incur any substantial cost or expense to Party B. 
  

	 	3.	 API Interface for Resume Download 

Party A agrees to provide Party B with the interface for resume database download of 58.com
(58同城), ganji.com (赶集网) and chinahr.com
(中华英才网) on [***] for Party B’s own business development and recruitment of relevant personnel. The total number of
daily resumes downloaded from the above three websites shall not exceed [***]. 
  

	 	4.	 Special Applicable Clause 

The Parties agree that, the provision by Party A to Party B of the resources under Article 1 hereof is subject to the precondition that more
than 40% (inclusive) of the equity interest in 58 Daojia Inc. on a fully-diluted basis (including the reserved equity interest for ESOP) is held by 58.com Inc.. The aforesaid shareholding percentage shall be more than 30% (inclusive) if 58 Daojia
completes the IPO. The performance by Party A and its affiliates of the obligations set forth in Article 3 under this Agreement is subject to the precondition that more than 30% (inclusive) of the equity interest in Party B shall be held by 58.com
Inc.. The Parties agree that the brand license set forth in Article 2 hereof shall not be restricted by the investment percentage. 
 The
above percentage of equity interest held by Party A in Party B shall be calculated based on the actual possessed interest under the legal structure, i.e. the shareholding by 58.com Inc. of the equity interest in 58 Daojia Inc. under the existing VIE
structure. If the Parties agree to rescind the VIE structure, the shareholding percentage under the new legal structure shall be calculated on the basis of actual shareholding percentage. 

The resources provided by Party A to Party B in accordance with this Agreement shall be limited to Party B’s use and shall not be
provided, resold or licensed to any third party other than Party B. In addition, in the event that Party B transfers the resources provided by Party A under this Agreement or grants the resources to a third party, Party A shall have the right to
stop providing the above resources. 

 Each of the Parties hereto understands and agrees that it enters into this Agreement on its
own behalf and on behalf of its affiliated companies and has the obligation to cause and ensure its affiliated companies to observe and perform this Agreement. 
  

	 	5.	 Intellectual Property 

Any materials and information provided by each Party and its affiliated companies to the other Party respectively for the purpose of this
Agreement and the intellectual properties of such materials and information shall not be changed as a result of the cooperation under this Agreement, unless otherwise stipulated in this Agreement or the relevant parties have executed an express
intellectual property assignment agreement. 
 Unless otherwise expressly stipulated in this Agreement or the relevant parties have executed
an express intellectual property assignment or license agreement, without the prior written consent of the right party, neither Party (and its affiliated companies) shall use or copy the patents, trademarks, names, marks, commercial information,
technology and other data materials, domain names, copyrights or other intellectual property of the other Party (and its affiliated companies) or apply for the registration of intellectual property similar to any of the foregoing intellectual
property. 
 Any new intellectual property formed by the Parties (and their affiliated companies) in the business cooperation shall be owned
by the actual business operator, unless otherwise provided in this Agreement. 
  

	 	6.	 CONFIDENTIALITY 

The Parties acknowledge that any oral or written information exchanged between the Parties in connection with this Agreement, this Agreement
and its contents are confidential information. Each Party shall maintain confidentiality of all such information and shall not disclose any relevant confidential information to any third party without the prior written consent of the other Party,
except that: (1) such information is already publicly available (other than through the violation of confidentiality obligations by the receiving Party or its affiliated companies or personnel); (2) such information shall be disclosed according
to the applicable laws, the requirement of competent authorities, the requirement of competent stock exchange, rules or regulations of the relevant stock exchange; or (3) such information is required to be disclosed by either Party to its
legal, financial or other advisors regarding the cooperation contemplated herein, provided, however, that such advisors shall be bound by the confidentiality obligations similar to those set forth in this Article. Each Party further undertakes to
use such confidential information provided by the other Party only in connection with the matters provided by this Agreement and shall destroy or return such confidential information upon the termination of this Agreement as requested by the other
Party. Any violation of this Article 5 by such Party’s affiliates or the staff or agency of such Party or its affiliates shall be deemed to be breach of this Agreement by such Party and such Party shall be liable for breach of this Agreement.
This Article shall survive the invalidity, rescission or termination of this Agreement for any reason. 
  

	 	7.	 Notices and Delivery 

All notices and other communications required or permitted to be given pursuant to this Agreement shall be delivered personally, sent by
registered mail, prepaid postage or commercial express service or by facsimile transmission to the address of such Party set forth below. A confirmation copy of each notice shall also be sent by email. The dates on which notices shall be deemed to
have been effectively given shall be determined as follows: 

	 	(1)	 Notices given by personal delivery, by express service or by registered mail, prepaid postage, shall be deemed
effectively given on the date of receipt or refusal at the address specified for notices. 

  

	 	(2)	 Notices given by facsimile transmission shall be deemed effectively given on the date of successful
transmission (as evidenced by an automatically generated confirmation of transmission). 

 For the purpose of notices, the
addresses of the Parties are as follows: 
 Party A: 

Address: Tower E, North America International Business Center, B No. 108 Beiyuan Road, Chaoyang District, Beijing 

Attn: [***] 
 Telephone: [***]

 E-mail: [***] 

Party B: 
 Address: Tower H2,
North America International Business Center, B No. 108 Beiyuan Road, Chaoyang District, Beijing 
 Attn: [***] 

Telephone: [***] 
 E-mail: [***] 
 Any Party may at any time change its address for notices by a notice delivered to the
other Party in accordance with the terms hereof. 
  

	 	8.	 Liability for Breach 

 

	 	(1)	 Any Party who materially breaches the provisions of Article 1 and Article 3 of this Agreement shall pay
compensation of USD 50,000,000 to the non-breaching Party. 

  

	 	(2)	 If Party A breaches the provisions of Article 2 hereof, it shall pay Party B the fair market value of the brand
of trademark as set forth in Article 2 as liquidated damages, but such liquidated damages shall not be less than USD 50,000,000. 

  

	 	(3)	 If Party A breaches the above Article 1, 2 and 3, the rights of Party B for claim against Party A for
liquidated damages in accordance with the above section (1) and (2) shall be cumulative and not exclusive. 

  

	 	9.	 Governing Law and Resolution of Disputes 

The execution, effectiveness, construction, performance, amendment and termination of this Agreement and the resolution of disputes hereunder
shall be governed by the laws of Hong Kong. 
 In the event of any dispute with respect to the construction and performance of this
Agreement, the Parties shall first resolve the dispute through friendly negotiations. If the Parties fail to resolve the dispute within 30 days after the consultation, each Parties may submit the relevant dispute to Hong Kong International
Arbitration Centre for arbitration, in accordance with its then effective arbitration rules. The arbitration shall be conducted in Hong Kong, and the language used in arbitration shall be English. The arbitration award shall be final and binding on
both Parties. 

 Upon the occurrence of any disputes arising from the construction and performance of this
Agreement or during the pending arbitration of any dispute, except for the matters under dispute, the Parties to this Agreement shall continue to exercise their respective rights under this Agreement and perform their respective obligations under
this Agreement. 
  

	 	10.	 Effectiveness 

This Agreement shall be effective as of the date when it is signed and sealed by the Parties or their authorized representatives. 

 

	 	11.	 Amendment 

Any amendment and supplement to this Agreement shall be made in writing. The amendment agreements and supplementary agreements related to this
Agreement that have been duly executed by the Parties shall be an integral part of this Agreement and shall have the same legal validity as this Agreement. 
  

	 	12.	 Assignment 

Without the prior written consent of the other Party, neither Party shall assign its rights and obligations hereunder to any third party;
provided, however, that either Party may designate its appropriate subordinate Affiliates to perform the cooperation matters based on specific needs. 
  

	 	13.	 Integrity 

Immediately upon the effectiveness of this Agreement, this Agreement constitutes the entire agreement and understanding reached by and among
the Parties hereto with respect to the subject matter set forth herein, and shall supersede all other agreements and understanding, both written and oral, between the Parties with respect to the subject matter set forth herein. 

 

	 	14.	 Independence 

If any provision of this Agreement is deemed to be invalid, illegal or unenforceable, the validity, legality and enforceability of other parts
and provisions of this Agreement shall not be affected thereby. The Parties shall negotiate in good faith with the principle of achieving the original commercial intention to the extent possible. 

 

	 	15.	 Force Majeure 

Once the Parties confirm that an event of force majeure occurs which causes the failure or delay to performance of this Agreement, either Party
may suspend the performance of this Agreement; provided, however, that it shall notify the other Party within 3 business days after becoming aware of such event (unless incapable of prompt performance due to an event of force majeure) and submit
details of such event and effective evidence within 15 days. If the effect of such force majeure fails to be eliminated within 30 days from the date of occurrence of such force majeure and the Parties fail to reach agreement for modification to this
Agreement, either Party has the right to terminate this Agreement, this Agreement shall be terminated from the date when one Party sends the termination notice to the other Party. 

“Force Majeure” refers to an event, which, beyond the reasonable control of the Parties to this Agreement, unforeseen or unavoidable,
makes it impossible for any Party to perform all or part of his obligations under this Agreement. Such events include but are not limited to acts of governments, changes in policies, earthquake, typhoon, flood, fire or other acts of nature, war or
any other similar events. 
 Force Majeure occurs after the breach of this Agreement shall not be released from such responsibility. 

	 	16.	 Counterparts 

This Agreement shall be made in six (6) originals, with each Party holding three (3) originals, and each original shall have the same
legal effect. 
 (The remainder of this page is intentionally left blank and signature pages follow) 

 IN WITNESS WHEREOF, this Business Cooperation Agreement has been signed by both parties or their authorized
representatives on the date first above written. 
  

			
	58.com Inc.
		
	By:	 	 /s/ Jinbo Yao

	Name:	 	Jinbo Yao
	Title:	 	Legal Representative
	
	Wuba Co., Ltd.
		
	By:	 	 /s/ Jinbo Yao

	Name:	 	Jinbo Yao
	Title:	 	Legal Representative
	
	Beijing Wuba Information Technology Co., Ltd.
		
	By:	 	 /s/ Jinbo Yao

	Name:	 	Jinbo Yao
	Title:	 	Legal Representative

 IN WITNESS WHEREOF, this Business Cooperation Agreement has been signed by both parties or their authorized
representatives on the date first above written. 
  

			
	58 Daojia Inc.
		
	By:	 	 /s/ Xiaohua Chen

	Name:	 	Xiaohua Chen
	Title:	 	Authorized Representative
	
	Beijing Wuba Daojia Information Technology Co., Ltd.
		
	By:	 	 /s/ Jinbo Yao

	Name:	 	Jinbo Yao
	Title:	 	Legal Representative
	
	Tianjin Wuba Daojia Life Service Co., Ltd.
		
	By:	 	 /s/ Jinbo Yao

	Name:	 	Jinbo Yao
	Title:	 	Legal Representative

 Appendix 1EX-10.8

 Exhibit 10.8 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

SUPPLY AGREEMENT 
 THIS SUPPLY
AGREEMENT is made and entered into this 27th day of February, 2020 (the “Effective Date”), by and between Dermata Therapeutics, LLC, a Delaware limited liability company, having a principal place of business at 3525 Del Mar
Heigts Rd. #322, San Diego, CA 92130 (“Dermata”), and LIMITED LIABILITY COMPANY “REKA-PHARM” (ОБЩЕСТВО С
ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ
“РЕКА-ФАРМ”), d.b.a Reka-Pharm, a Russian Federation limited liability company, registered in Russia under the primary state registration number [***] and, as of the date hereof, having a
principal place of business at [***] (“Reka-Farm”) and Mikhail Petrovichev. 
 WHEREAS, Reka-Farm is a supplier of Spongilla and
Material (as such terms are defined below); and 
 WHEREAS, Dermata wishes to purchase Spongilla and Material from Reka-Farm on the terms and
conditions of this Agreement to develop proprietary dermatological products; and 
 WHEREAS, Reka-Farm is willing to supply Spongilla and Material to
Dermata on the terms and conditions of this Agreement; 
 NOW, THEREFORE, in consideration of the acknowledgements, confirmations, representations,
warranties and covenants contained herein, Dermata and Reka-Farm (which shall each also hereinafter be referred to as a “Party” or together as the “Parties”) hereby agree as follows: 

ARTICLE I. 

DEFINITIONS 
 The following terms,
whether used in the singular or plural, have the respective meanings set forth below: 
  

	1.1	 “Acceptance Criteria” means the criteria set forth in the Collection Protocol, as developed by
Dermata and modified from time to time, setting forth requirements for acceptance of any Material to be Supplied to Dermata. 

  

	1.2	 “Accepted Purchase Order” shall have the meaning set forth in Section 2.5.2.

  

	1.3	 “Affiliate” means any individual, corporation, association, or other business entity, which
directly or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of “Affiliate,” the term “control” shall mean, as to an entity, (a) direct or indirect
ownership of fifty percent (50%) or more of the voting interests or other ownership interests in the entity in question; (b) direct or indirect ownership of fifty percent (50%) or more of the interest in the income of the entity in question; or
(c) possession, directly or indirectly, of the power to direct or cause the direction of management or policies of the entity in question (whether through ownership of securities or other ownership interests, by contract or otherwise).

  

	1.4	 “Agreement” means this Supply Agreement. 

 

	1.5	 “Applicable Laws” means (i) all Russian federal and local (regional or municipal) laws,
rules, and regulations applicable to the Collection, Processing and Testing of Spongilla and Testing and Supply of Material under this Agreement, including, but not limited to, the Ministry of Agriculture of the Russian Federation Regulation No 501
dated 6 October 2017 “On approval of the list of types 

  
 1 

	 	
of aquatic biological resources with respect to which industrial fisheries in internal waters could be carried out in the Russian Federation, excluding inland sea waters of the Russian
Federation, and on declaration of regulations of the Ministry of Agriculture of the Russian Federation to be no longer in force” (ii) all laws, rules and regulations of any governmental authority or body worldwide applicable to this Agreement
and the licensing, importation, manufacturing, use and sale of Material and Products, and (iii) all rules, guidelines and regulations applicable to the manufacturing, development and sale of the Material and a Products as enacted and enforced
by a Regulatory Authority, including, but not limited to, the GACP. 

  

	1.6	 “Batch” means a specific quantity of Material that is intended to be of uniform character and
quality, within specified limits, and is Collected, Processed, Tested and Supplied during the same year from a Collection Site, in accordance with the Documentation, as defined by the Batch Record. 

 

	1.7	 “Batch Record” means all Documentation, including information relating to the production and
control of each Batch, demonstrating each step in the Collection, Processing, packing, and storage of a Batch. 

  

	1.8	 “Business Day” means any day other than Saturday, Sunday or any statutory holiday in the
United States of America. 

  

	1.9	 “Calendar Quarter” means each of the periods of time from (a) January 1 through
March 31, (b) April 1 through June 30, (c) July 1 through September 30, and (d) October 1 through December 31. 

  

	1.10	 “Certificate of Analysis” shall have the meaning set forth in Section 5.1.

  

	1.11	 “Certificate of Compliance” means a statement from Reka-Farm certifying that a Batch has been
Collected, Processed and Tested in accordance with the Documentation and Applicable Laws. 

  

	1.12	 “Certificate of Taxonomic Identification” means a document certifying Spongilla species
authenticity by a qualified expert using organoleptic, macroscopic, and microscopic techniques against known standards. 

  

	1.13	 “Collection,” “Collected,” and “Collecting” means all
operations of Reka-Farm and/or Reka-Farm Contractors related to the scheduling and collecting of Spongilla that follows the Collection Protocol requirements and other requirements for collection of Spongilla hereunder. 

 

	1.14	 “Collection Date” means the date in each calendar year in which Reka-Farm has scheduled to
begin Collecting Spongilla. 

  

	1.15	 “Collection Protocol” means a collection management plan which includes the minimum collection
quantities of Spongilla required to be Collected, prospective Collection Sites, the Collection Date and descriptions and instructions for Collecting and Processing Spongilla and the collection log book. 

 

	1.16	 “Collection Site” means the geographic area designated in the Collection Protocol and within
which Reka-Farm will Collect each Batch of Spongilla to be Delivered. 

  

	1.17	 “Commercially Reasonable Efforts” means the level of effort as is customary in the
pharmaceutical industry for carrying out in a reasonably sustained manner a particular task or obligation, including Reka-Farm’s obligations relating to Collecting, Processing, Testing and Supply. 

  
 2 

	1.18	 “Confidential Information” shall have the meaning set forth in Section 7.1.

  

	1.19	 “Cosmetic Product” means any product that (a) contains Spongilla solids, not to exceed
[***] by weight of the total solids weight, (b) is formulated with at least one (1) other inactive component, for example: gel, cream or lotion, in a single package and (c) is not sold as a “drug” in any country in
the Territory as defined in Sec. 201(g)(1) of the Act. 

  

	1.20	 “Deliverables” shall have the meaning set forth in Section 8.3. 

 

	1.21	 “Delivery” and “Delivered” shall have the meaning set forth in
Section 3.2. 

  

	1.22	 “Delivery Date” means the date contained in a Purchase Order or an Accepted Purchase Order, as
the case may be, on which Dermata requests Delivery of the Material from Reka-Farm to Dermata, an Affiliate of Dermata or a Third Party designated by Dermata. 

 

	1.23	 “Documentation” means the (i) Collection Protocol; (ii) inspection procedures and
specifications for Spongilla and desiccated Spongilla (including physical, and organoleptic specifications); (iii) desiccated Spongilla Processing procedures; (iv) in-process specifications;
(v) processed Spongilla packaging procedures and specifications and labeling; (vi) Material specifications; (vii) Acceptance Criteria; (viii) the Certificates of Analysis, (ix) Certificates of Taxonomic Identification, and
(x) Certificates of Compliance, in the case of each of (i) to (x) as may be amended or revised from time to time by mutual written agreement of the Parties, or as required by a Regulatory Authority. 

 

	1.24	 “Equipment” means all materials, screens, tools, machines, packaging and labeling components,
and all other supplies of any kind used in connection with Collection, Processing, Testing and Supply. 

  

	1.25	 “Exploit,” “Exploiting” or “Exploitation means sell, provide,
process, test, develop, formulate, have made, make, use, offer for sale, market, advertise, promote, import, export, supply, commercialize or otherwise distribute of. 

 

	1.26	 “Facility” means the Reka-Farm’s facility located at [***]. 

 

	1.27	 “Force Majeure Event” means causes beyond a Party’s reasonable control, including and
without limitation, civil disturbances, fire, explosions, acts of God, severe weather, floods, disease, war, acts of a public enemy, terrorism, and government action. 

 

	1.28	 “Forecast” shall have the meaning set forth in Section 2.5.1. 

 

	1.29	 “Good Agricultural and Collection Practices”, “GACP” shall have the meaning
set forth in (a) the World Health Organization’s “WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants,” and (b) the European Medicines Agency’s “Guideline on Good Agricultural
and Collection Practice (GACP) for Starting Materials of Herbal Origin”. 

  

	1.30	 “Intellectual Property Rights” means (i) patents, patent disclosures and inventions
(whether patentable or not), (ii) trade secrets, know-how and other confidential information, and (iii) all other intellectual property rights, in each case whether registered or unregistered and
including all applications for, and renewals or extensions of, such rights, and all similar or equivalent rights or forms of protection in any part of the world. 

 

	1.31	 “Material” or “Spongilla Raw Material” means products comprising Spongilla
that have been (a) 

  
 3 

	 	
Collected, Processed, and Tested by Reka-Farm and/or Reka-Farm Contractors, and (b) Supplied by Reka-Farm to Dermata in accordance with the terms and conditions of all Applicable Laws, this
Agreement and the Quality Agreement. 

  

	1.32	 “Net Sales” shall mean for any period, the gross amount recorded for such period by Dermata on
their books and records, in accordance with GAAP with respect to sales of a Products in the Territory to Third Parties for any use in human medicine after deducting (such amounts determined in good faith by Dermata) (i) normal and customary
trade and quantity discounts actually taken or allocated, (ii) rebates and chargebacks, (iii) any customary allowances for damaged or returned goods or any credits actually accepted for Products destroyed in the field pursuant to
Dermata’s approval, (iv) retroactive price reductions or adjustments, (v) sales or excise taxes, (vi) shipping, freight and handling charges, and (vii) insurance charges. In addition, the supply of the Products for
(a) prototypes, test samples, demonstrations or marketing units provided by Dermata to a Third Party not in exchange for monetary consideration, (b) charitable donations or compassionate use, (c) any clinical study materials used in
any clinical study, or (d) any returns or recalls of Products for which Dermata provides a refund of the purchase price paid by a Third Party for such returned or recalled unit of Products shall not be included within the computation of Net
Sales. For the avoidance of doubt, and by way of example, “allowances” for the purposes of the calculation of Net Sales include (i) credits given to customers at the time of list price increases, including fees for inventory
management agreements with wholesalers or distributors, (ii) credits given to customers for stocking allowances upon the launch of the Products (or any new version thereof), and (iii) credits given (or payments made) to customers or
patients based upon the redemption of a coupon or free trial offer. 

  

	1.33	 “Non-Conforming Material” shall have the meaning set
forth in Section 5.2. 

  

	1.34	 “Pre-shipment Sample” shall have the meaning set forth
in Section 5.1. 

  

	1.35	 “Products” means products that contain Material, alone or in combination with other active or
inactive ingredients. 

  

	1.36	 “Process,” “Processed,” “Processing” means all operations of
Reka-Farm, its Affiliates and and/or Reka-Farm Contractors, including but not limited to sorting, cleaning, drying, processing, grinding, sizing, and milling, of Collected Spongilla, necessary to Supply Material that meets the applicable
Documentation and other requirements for Spongilla and Material hereunder. 

  

	1.37	 “Purchase Order” shall have the meaning set forth in Section 2.5.2.

  

	1.38	 “Purchase Price” shall have the meaning set forth in Section 3.1. 

 

	1.39	 “Quality Agreement” shall have the meaning set forth in Section 4.7.

  

	1.40	 “Recall” shall have the meaning set forth in Section 5.5. 

 

	1.41	 “Regulatory Authority” means any governmental or regulatory agency with authority over
Reka-Farm’s operations pursuant to this Agreement, or over Dermata’s development or use of the Material, or the development, testing, and sale of Products. 

 

	1.42	 “Reka-Farm Contractors” means any contractors or other Third Parties retained or used by
Reka-Farm to perform any of Reka-Farm’s obligations under this Agreement. 

  
 4 

	1.43	 “Representatives” shall have the meaning set forth in Section 7.2. 

 

	1.44	 “Royalty” shall have the meaning set forth in Section 3.4. 

 

	1.45	 “Royalty Reporting Quarter” means each Calendar Quarter during the Term subsequent to the
first commercial sale of a Product by Dermata or its Affiliate. 

  

	1.46	 “Spongilla” means sponges of: Phylum: Porifera; Class: Demospongia; Family: Spongillidae;
Genus: Spongilla; Species: Spongilla Lacutris; fresh-water, wild-grown. 

  

	1.47	 “Spongilla Licenses” means one or more licenses or permits granted by the government of the
Russian Federation and that are necessary in order for Reka-Farm to Collect Spongilla within a Collection Site and Process and Supply Spongilla in accordance with all Applicable Laws, including (but not limited to) permission to catch aquatic
biological resources. 

  

	1.48	 “Supply,” “Supplying,” and “Supplied” mean all operations of
Reka-Farm related to the packaging, labeling, warehousing, storing, and shipping of Material that has been Collected, Processed, and Tested, that meets the applicable Acceptance Criteria and other requirements for Material hereunder.

  

	1.49	 “Territory” means worldwide, but excluding the Russian Federation. 

 

	1.50	 “Term” shall have the meaning set forth in Section 10.1. 

 

	1.51	 “Test,” “Tested,” and “Testing” means all testing of
Spongilla and the Materials conducted by Reka-Farm and/or Reka-Farm Contractors conducted at the Testing Facility or by the Testing Expert, including quality control testing and acceptance testing as required to meet the Documentation and other
requirements for Material hereunder. 

  

	1.52	 “Testing Expert” shall have the meaning set forth in Section 5.3.1.

  

	1.53	 “Testing Facility” means the Reka-Farm laboratory located at [***], or Reka-Farm
Contractor’s facility where Testing is conducted. 

  

	1.54	 “Third Party” means a party other than Dermata or Reka-Farm. 

 

	1.55	 “Trademarks” means all rights in and to trademarks, service marks, trade dress, trade names,
brand names, logos, symbols, trade dress, corporate names and domain names and other similar designations of source, sponsorship, association or origin, together with the goodwill symbolized by any of the foregoing, in each case whether registered
or unregistered and including all registrations and applications for, and renewals or extensions of, such rights and all similar or equivalent rights or forms of protection in any part of the world. 

Unless the context of this Agreement otherwise requires: (a) words of any gender include each other gender; (b) words using the singular or plural
number also include the plural or singular number, respectively; (c) the terms “hereof,” “herein,” “hereby,” and derivative or similar towards refer to this entire Agreement; (d) the terms “Section”
refer to the specified section of this Agreement; (e) the term “or” has, except where otherwise indicated, the inclusive meaning represented by the phrase, “and/or”; (f) the term “including” means
“including, without limitation”; and (g) “days” refers to calendar days. All references to “$” or “Dollar” amounts hereunder shall be deemed to be U.S. Dollars, and all payments due hereunder shall be made in
U.S. Dollars. 

  
 5 

 ARTICLE II. 

SUPPLY OF MATERIAL 

2.1    Collection and Processing of Spongilla; Processing, Testing, and Supply of Material. 

2.1.1    Collection of Spongilla only within the Collection Site. Reka-Farm will Collect Spongilla only within the
Collection Site(s) and in conformance with the Documentation, unless otherwise agreed to in writing by the Parties. Reka-Farm will promptly notify Dermata in writing if Reka-Farm determines that any Batch, or any portion of any Batch, of Spongilla
is Collected outside a Collection Site. Reka-Farm shall ensure that any and all Spongilla Licenses, registrations, and Regulatory Authority approvals required by Applicable Laws are obtained and maintained during the Term in connection with each
Collection Site, the Equipment, and processes used in connection with Collecting and Processing of the Spongilla by Reka-Farm and/or Reka-Farm Contractors. 

2.1.2    Collection Protocol. Not less than sixty (60) days prior to the Collection Date in each calendar
year, the Parties shall mutually approve the Collection Protocol for such year. 
 2.2    Processing and Testing of Spongilla and
Material. Reka-Farm and/or Reka-Farm Contractors will (a) Process Spongilla and Materials only at the Collection Sites and the Facility, and (b) Test Spongilla and Materials only at the Test Facility, each of (a) and (b) in
conformance with all Applicable Laws, the terms and conditions of this Agreement, and the Quality Agreement, unless otherwise agreed to by the Parties in writing. Reka-Farm will immediately provide notice to Dermata in writing if any of the Material
Supplied to Dermata is Processed or Tested at a facility other than the Facility or the Testing Facility. All Material derived from Collections after the year 2019 must be stored at controlled room temperature and protected from light and moisture.
Reka-Farm shall ensure the Facility, the Testing Facility, and Equipment within is maintained in a state of repair and operating efficiency consistent with the requirements of the Documentation and all Applicable Laws. 

2.3    Supply of Material. 

2.3.1    Exclusivity of Supply. During the Term, and subject to the terms and conditions of this Agreement,
Reka-Farm shall sell, provide, or otherwise supply Spongilla Raw Material exclusively to Dermata for use in the Territory. Reka-Farm shall not, directly or indirectly through Affiliates, agents, Reka-Farm Contractors, representatives or
distributors, except through Dermata hereunder, Exploit Spongilla Raw Material or any product containing Spongilla that is not a Cosmetic Product to (a) any Third Party in the Territory, or (b) to any Third Party that Reka-Farm knows, or
has reason to know, is or intends to Exploit in the Territory. For the avoidance of doubt, Reka-Farm may sell Cosmetic Products to Third Parties in the Territory. If during the Term any Third Party is found to be Exploiting Spongilla Raw Material in
the Territory that was provided by Reka-Farm or found to be Exploiting any product that contains Spongilla Raw Material provided by Reka-Farm that is not a Cosmetic Product produced or manufactured by Reka-Farm, Reka-Farm shall immediately stop
providing all products to such Third Party and shall terminate any and all agreements with such Third Party. The Parties hereto recognize that the restrictions contained herein, and the terms of, this Section 2.3.1 are properly required
for the adequate protection of Dermata’s rights under this Agreement and agree that if any provision in this Section 2.3.1 is determined by any court to be unenforceable by reason of its extending for too great a period of time or over too
great 

  
 6 

 
a geographic area, or by reason of its being too extensive in any other respect, such covenant shall be interpreted to extend only for the longest period of time and over the greatest geographic
area, and to otherwise have the broadest application as shall be enforceable. 
 2.3.2    Purchase of Supplied
Material. Subject to the terms and conditions of this Agreement, Dermata agrees to purchase the Materials from Reka-Farm in quantities to be determined by Dermata in Purchase Orders, in its sole discretion. Dermata may supply purchased Materials
to Third Parties and Affiliates. 
 2.4    Documentation. Reka-Farm shall Collect and Process Spongilla and Test and Supply
Material in accordance with the applicable Documentation and all Applicable Laws. At least fifteen (15) business days prior to the Delivery Date specified in an Accepted Purchase Order, Reka-Farm shall send to Dermata the following information:
(i) the number of Batches from each specified Collection Site, as specified in a Purchase Order, (ii) a Certificate of Analysis, (iii) a Batch Record, (iv) a Certificate of Taxonomic Identification, and (v) a Certificate of
Compliance for Dermata’s review and approval. For the avoidance of doubt, Reka-Farm shall not Supply to Dermata hereunder, and Dermata shall have no obligation to accept from Reka-Farm, any Material in contravention of this Section 2.4,
unless mutually agreed to in writing by the Parties. 
 2.4.1    Documentation and Process Changes. 

(a)    Specification and Process Changes. In the event that (i) any amendments are made to the
Documentation, (ii) any additional Testing for the Material, any licensing or any other procedure is deemed necessary by Dermata to comply with Applicable Laws, (iii) or any changes to the Documentation are requested by any Regulatory
Authority or by Dermata in response to findings resulting from a quality audit, and any of (i) to (iii) require changes to the Collection, Processing, or Testing or the Spongilla, or to the Facility, the Testing Facility or Reka-Farm’s
other activities under this Agreement, Dermata promptly shall provide Reka-Farm with a description of such changes. Reka-Farm shall use Commercially Reasonable Efforts to implement such changes in accordance with the change control procedures
specified in the Quality Agreement, at Reka-Farm’s sole cost. In the event Reka-Farm demonstrates through written evidence that its operations are not capable of incorporating the proposed changes within the timeframe requested to comply with
such changes, then the Parties will engage in good faith discussions with respect to the identification and implementation of arrangements that will permit Reka-Farm to incorporate the proposed changes into its operations. 

(b)    Dermata Approval Required. Notwithstanding the foregoing provisions of this Section 2.4.1, Reka-Farm
shall not, in any material respect, amend, modify or supplement the Documentation or the Acceptance Criteria for the Material without the prior, written consent of Dermata. 

2.5    Forecasts; Orders. 

2.5.1    Forecasts. As specified herein, Dermata will provide Reka-Farm with a rolling two-year forecast of Dermata’s anticipated requirements of Material (each, a “Forecast”), specifying the Collection year or years desired. The first Forecast will be provided not later than one
hundred and twenty (120) days after the Effective Date, and Forecast updates will be provided semi-annually by Dermata starting on January 1, 2021. Reka-Farm guarantees the ability to Supply to Dermata the quantity specified in each
Forecast for the first twelve (12) months of each Forecast. All Forecasts will be non-binding on Dermata. 

2.5.2    Purchase Orders and Acceptance. Dermata may submit to Reka-Farm one or more purchase orders for the
purchase of Material (each, a “Purchase Order”) at least thirty (30) days prior to the 

  
 7 

 
requested Delivery Date, which Purchase Orders will contain (a) the Collection year(s) from which such Material should be derived, (b) the quantity of Material to be Delivered,
(c) the number of Batches, (d) any requirement for a Pre-shipment Sample, (e) the requested Delivery Date(s), and (f) any applicable shipping information. Within ten (10) days after
Reka-Farm’s receipt of each Purchase Order, Reka-Farm will provide Dermata with a written notice of acceptance or rejection of each such Purchase Order, an acceptance of which will include confirmation of the requested Delivery Date(s) and
quantities of Materials to be Delivered (each, an “Accepted Purchase Order”). Purchase Orders which Reka-Farm does not reject within such ten (10) day period will be deemed an Accepted Purchase Order. In the event Reka-Farm
notifies Dermata that it believes that changes to the Purchase Order are necessary, the Parties shall enter into good faith negotiations regarding the changes requested by Reka-Farm. Upon written agreement of the Parties, Dermata will re-issue the Purchase Order incorporating such changes, and the re-issued Purchase Order shall be deemed an Accepted Purchase Order. The terms and conditions contained in an
Accepted Purchase Order shall be binding on the Parties. Reka-Farm shall be obligated to deliver to Dermata, on or prior to the Delivery Date, the Batches that conforms to the Documentation in the quantity set forth in an Accepted Purchase Order.
Subject to the terms and conditions of Article V, Dermata shall be obligated to purchase the quantity of conforming Materials set forth in the Accepted Purchase Order, and at the Purchase Price. In the event that the terms and conditions of any
Purchase Order or Accepted Purchase Order conflict with the terms and conditions of this Agreement or the Quality Agreement, the terms of this Agreement or the terms of the Quality Agreement, as the case may be, shall prevail. 

2.6    Reka-Farm Responsibilities. Reka-Farm shall, at its sole cost, be responsible for purchasing and maintaining all materials,
Equipment, and Spongilla Licenses, paying and training all personnel and Reka-Farm Contractors and acquiring any other documentation required to Collect and Process Spongilla and Test and Supply the Material in accordance with all Applicable Laws
and the terms and conditions of this Agreement and the Quality Agreement. 
 2.7    Subcontracting. Upon written notification to
Dermata, Reka-Farm may delegate or subcontract its Collecting, Processing, Testing, and Supply obligations hereunder, and may delegate or subcontract other of its obligations hereunder to any of its Affiliates or Reka-Farm
Contractors; provided, however, that such delegation or subcontract is not prohibited by Applicable Laws and that Reka-Farm shall fully and unconditionally guarantee the full and timely performance by any such Affiliates or
Reka-Farm Contractors, which guarantee shall be a continuing guaranty and remain in full force and effect for so long as there shall remain any obligations (including, without limitation, any indemnification obligations) or any representations or
warranties of Reka-Farm under this Agreement. Any delegation or subcontracting by Reka-Farm of any of its rights or obligations under this Agreement shall not relieve Reka-Farm of any of its obligations hereunder. 

2.8    Failure to Supply. In the event of an actual or anticipated inability to Supply Material in accordance with the terms and
conditions of an Accepted Purchase Order (“Failure to Supply”), Reka-Farm shall promptly notify Dermata in writing and, unless otherwise agreed by the Parties, all available quantities of Spongilla then-available to Reka-Farm,
whether or not conforming to the Documentation, shall be made available to Dermata on a first priority basis until the terms and conditions of the applicable Accepted Purchase Order are met in full. In all instances of Failure to Supply, Reka-Farm
will, in consultation with Dermata, use Commercially Reasonable Efforts to immediately resolve the conditions that led to the Failure to Supply at Reka-Farm’s sole expense. Except in the event of a Failure to Supply caused by the occurrence of
a Force Majeure Event, a Failure to Supply event shall be deemed a material breach by Reka-Farm of the terms and conditions of this Agreement. 

2.9    Observation. Reka-Farm grants to Dermata a right, upon at least thirty (30) days written notice to Reka-Farm, to have
one or more Dermata personnel or Third-Party contractors present at a Collection Site during Collecting and Processing Spongilla, at the Facility during Processing, and/or at the Testing Facility during Testing. This observation right shall include
having a Dermata designated representative at the Facility full-time. 

  
 8 

 ARTICLE III. 

PRICE, ROYALTIES; DELIVERY AND PAYMENT TERMS 

3.1    Material Price. Reka-Farm will Supply Material to Dermata, as specified in each Accepted Purchase Order, and meeting the
requirements of the Documentation, all Applicable Laws, the terms and conditions of this Agreement and the Quality Agreement, and, subject to the terms and conditions of this Agreement, Dermata shall pay to Reka-Farm the price of [***] (the
“Purchase Price”) of such Delivered Material. 
 3.2    Delivery Terms. Reka-Farm shall prepare all Material for
shipment to Dermata, or to Dermata’s designated consignee, in conformance with the terms and conditions of the applicable Accepted Purchase Order, this Agreement and the Quality Agreement, unless otherwise agreed to in writing by the Parties.
Unless otherwise set forth in an Accepted Purchase Order, all shipments of Material shall be delivered EXW (Incoterms 2010) the Facility (“Delivery” and/or “Delivered”), freight collect, by a common carrier
designated by Dermata. Dermata shall procure, at its cost, insurance covering damage or loss of Material during shipping from the Facility to Dermata’s designated receipt location. Reka-Farm shall prepare each Batch for shipment in accordance
with the instructions in the applicable Accepted Purchase Order. Title to the Material shall pass from Reka-Farm to Dermata upon Dermata or a common carrier designated by Dermata taking possession of the Material. 

3.3    Method of Payment. Reka-Farm will invoice Dermata upon completion of Delivery of each Batch as designated in each Accepted
Purchase Order, and all undisputed invoices shall be due and payable thirty (30) days from the date of Dermata’s receipt of such invoice. All payments hereunder shall be made in United States Dollars. Dermata shall make all payments
pursuant to this Agreement by wire transfer to a bank account as designated in writing by Reka-Farm. In the event Dermata disputes any portion of an invoice in good faith, including but not limited to Dermata’s rejection of a Batch or a portion
of a Batch Delivered by Reka-Farm to Dermata in accordance with Section 5.2, Dermata shall be permitted to suspend payment of the disputed invoice until such dispute is resolved and the Parties shall work together in good faith to resolve any
such disputes in an expeditious manner. 
 3.4    Royalty Payments. Subject to the terms and conditions stated herein and during
the Term, Dermata shall pay to [***] a royalty of [***] of the Net Sales of Products sold by Dermata in the Territory (“Royalty”). Within forty-five (45) days after the end of each Royalty Reporting Quarter, Dermata
shall submit to [***] a written report setting forth, for such preceding Calendar Quarter, the number of units of Products sold and the calculation of the Royalty due, if any, to [***] pursuant to this Section 3.4, along with
payment of the amounts so due. All payments shall be made in United States Dollars. Sales made in currencies other than United States Dollars shall be converted to United States Dollars in accordance with the exchange rate conversions used by
Dermata in preparation of its regularly prepared financial statements, treating United States Dollars as the reporting currency. Dermata may adjust amounts paid to [***] in a year, by set-off against
future payments due hereunder on a quarterly basis, of any overpayment of Royalties revealed in Dermata’s year-end audit for such year. 

3.5    Withholding Taxes. Where required to do so by Applicable Laws or order of a governmental body, Dermata shall withhold taxes
required to be paid to a taxing authority in connection with any payments to Reka-Farm hereunder, and, upon written request from Reka-Farm, Dermata shall furnish Reka-Farm with evidence of such withholding and payment. Dermata shall cooperate with
Reka-Farm in obtaining exemption from withholding taxes where available under Applicable Laws, or recovering the same where an exemption is not available. 

  
 9 

 3.6    Interest. Any undisputed amounts due from either Party to the other Party
under this Agreement, or any portion thereof, that are not paid when due, shall bear interest equal to one percent (1.00%) per month calculated on the number of days such payment is delinquent and compounded monthly, but in no event higher than the
allowable legal rate. All payments hereunder shall be made in United States Dollars by wire transfer to a bank account as designated in writing by the Party to be paid. 

ARTICLE IV. 

REGULATORY MATTERS 

4.1    Specification Requirements; Change Requests. Dermata shall be solely responsible for establishing the appropriate Acceptance
Criteria and for approving the master Batch Record and Collection Protocol for the Material. After Reka-Farm has upgraded the Facility to Dermata’s satisfaction, Dermata shall bear all reasonable external expenses incurred by Reka-Farm to
comply with revisions to the Acceptance Criteria and Collection Protocol established by Dermata; provided, however, that (a) Reka-Farm shall provide to Dermata an estimate in writing of all such expenses to be incurred by Reka-Farm with
respect to such upgrades, and Dermata shall be responsible to reimburse Reka-Farm only for those expenses and in those amounts for which Dermata agrees in writing prior to those expenses being incurred; (b) such expenses shall not include any
internal costs incurred by Reka-Farm, including wages, salaries, overhead, or other amounts for which Reka-Farm bears an obligation under this Agreement; and (c) if Dermata approves the estimate, Reka-Farm shall provide Dermata with copies of
invoices, receipts, agreements and other documentation reasonably requested by Dermata to support all such expenses. In the event that Dermata does not approve the expense estimate provided by Reka-Farm, the Parties shall work together to resolve
the issue in good faith. Reka-Farm shall be solely responsible for maintaining the documentation, and the conduct of all activities relating to the Collecting, Processing, Testing, and Supply of the Material in conformance with the Documentation and
all Applicable Laws. 
 4.2    Inquiries from Regulatory Authorities. Any inquiries received by Reka-Farm from any Regulatory
Authority that relate, directly or indirectly, to Spongilla, the Material and/or Products, Reka-Farm will promptly notify Dermata of the same, and, where permitted by Applicable Law, Dermata shall be solely responsible for any communication with the
applicable Regulatory Authority relating to such inquiry and Reka-Farm will assist Dermata, at Dermata’s expense, in responding to all such inquiries. 

4.3    Notification of Certain Events. Reka-Farm shall notify Dermata in writing promptly, but in any case, within one
(1) business day upon Reka-Farm becoming aware of any: 
 (a)    pending or threatened litigation, governmental
investigation, inspection, inquiry, proceeding or action involving Reka-Farm, the Material, a Collection Site, the Facility, or the Testing Facility to the extent it relates or may relate, directly or indirectly, to such Material or any portions of
a Collection Site, the Facility, or Testing Facility, systems or processes related in any way to the Collecting and Processing of Spongilla and the Processing and Supply of the Material; 

(b)    defective or adulterated Material provided to Dermata hereunder; and 

(c)    any Material provided to Dermata hereunder that fails to meet Acceptance Criteria or to comply with Applicable
Laws. 
 Reka-Farm shall promptly (a) forward to Dermata copies of any correspondence and fully

  
 10 

 
investigate such matters and provide to Dermata a written draft report of its investigation for Dermata’s comment. To the extent any such matter relates to matters outside the Applicable
Laws, Dermata shall bear the expenses of such investigation. Reka-Farm will also provide Dermata with all reasonable assistance requested by Dermata in connection with adverse experiences and customer complaints to the extent they relate to the
Material supplied by Reka-Farm under this Agreement. 
 4.4    Regulatory Inspections. In the event of any inspections by a
Regulatory Authority of Reka-Farm, a Collection Site, the Facility, or the Testing Facility of which Reka-Farm becomes aware, and which pertain to or have any quality implications for any Material supplied under this Agreement, or if such inspection
may materially affect Reka-Farm’s ability to provide Material to Dermata under this Agreement, Reka-Farm agrees to: 

(a)    notify Dermata in writing promptly but in any case, within two (2) business days; 

(b)    if applicable, provide copies of any notices or communications related to such inspections to Dermata and to allow
Dermata to participate in and approve the responses to any questions posed by the Regulatory Authority relating to the Material; and 

(c)    not disclose information or materials to the applicable Regulatory Authority(ies) that are not required to be
disclosed by Reka-Farm, without the prior written consent of Dermata, which consent shall not unreasonably be withheld or delayed. Such information and materials include, but are not limited to: (i) financial data and pricing data;
(ii) sales data; and (iii) personnel data. 
 Reka-Farm shall respond fully and accurately, with Dermata’s comment and
approval, to all inquiries directed to it by any Regulatory Authority and allow such Regulatory Authority, to inspect, audit and review each Collection Site, the Facility, or Testing Facility and all procedures, practices, books, records, and
documents relating to the Collection, Processing, Testing, and Supply of any Materials to the extent requested by such Regulatory Authority. Dermata shall have the right to have one or more employees or designated Third Parties on-site during any such inspections. No inspection by a Regulatory Authority shall relieve Reka-Farm of its obligations to deliver Material ordered by Dermata pursuant to the terms and conditions of an Accepted
Purchase Order, or affect Dermata’s right to pursue any remedies, in law or equity, that might be available to it. The provisions of this Clause are subject to the mandatory rules of the Applicable Laws to the contrary. 

4.5    Dermata Audit Rights. Reka-Farm grants to Dermata the right, once per Calendar Year during Collecting, Processing, Testing,
and Supply, and upon at least thirty (30) days written notice to Reka-Farm, to perform an audit during the entire Collection, Processing, Testing and Supply periods of any Collection Site, the Facility, and the Testing Facility, including all
records for Material supplied under this Agreement; provided, however, that Dermata’s inspection rights hereunder may be extended for additional time periods as reasonably required by Dermata in the event that any such inspection,
or any inspection by a Regulatory Authority, discloses any material failure of Reka-Farm to fully comply with terms and conditions of this all Applicable Laws, Agreement and the Quality Agreement. Any such audit will be at Dermata’s expense.

 4.6    Record Retention. Reka-Farm shall retain or cause the retention of originals of all Batch Records and other records or
documentation generated by it in connection with the Collecting and Processing of Spongilla and the Processing and Supply of Material under the terms of this Agreement, and all records which may be reasonably required by Dermata in the event of a
Recall or adverse drug event in the Territory, for a period of five (5) years from the date any such records were created, provided that prior to the destruction of any such records Reka-Farm shall provide thirty (30) days’ prior,
written notice to Dermata and Dermata shall have the right to take possession of such records, at its expense. 

  
 11 

 4.7    Quality Agreement. The Parties shall cooperate in good faith to develop a
mutually acceptable Quality Agreement within [***] after the Effective Date (the “Quality Agreement”). In the event the Quality Agreement contains provisions that are not inconsistent with, but in addition to, the terms set
forth herein, the Quality Agreement shall be supplemental to the terms and conditions set forth in this Agreement. Notwithstanding the foregoing or anything in this Agreement or the Quality Agreement to the contrary, in the event of any conflict or
inconsistency between the provisions of this Agreement and the provisions of the Quality Agreement, the provisions of this Agreement shall govern. 

ARTICLE V. 

CERTIFICATE OF ANALYSIS; INSPECTION; RETURNS, RECALLS 

5.1    Certificate of Analysis and Pre-Shipping Control Sample. Reka-Farm shall Test, or
have tested, each Batch to be Supplied to Dermata using the qualified and validated analytical testing methodologies set forth in the Documentation. Prior to the Delivery of each Batch Supplied to Dermata, Reka-Farm shall prepare for Dermata a
(i) sample of each Batch (“Pre-shipment Sample”), if included in an Accepted Purchase Order, (ii) a certificate of analysis, approved by a responsible representative of the quality
assurance function at Reka-Farm, (a) stating that the Material being shipped has been processed, tested, stored and fully conforms to the Acceptance Criteria, the terms and conditions of this Agreement and the Quality Agreement;
(b) setting forth the testing methodology employed in making the foregoing determination and the results generated by such tests; and (c) confirming compliance with all Applicable Laws with respect to the Collection and Processing of
Spongilla and Testing and Supply of the Material (“Certificate of Analysis”), and (iii) a Certificate of Taxonomic Identification. 

5.2    Acceptance of Batches of Material by Dermata. Each Batch Supplied by Reka-Farm shall be Delivered in accordance with the
terms and conditions of this Agreement and any Accepted Purchase Order. Dermata’s acceptance of any Delivered Batch is subject to Dermata’s reasonable inspection and testing of each Pre-shipment
Sample, if requested, and the Batch following Delivery. Any Batch, or any portion of any Batch, may be rejected by Dermata if any such Pre-shipment Sample, Batch, or any portion of any Batch fails to conform
to all Applicable Laws, the Documentation, the terms and conditions of this Agreement or the terms and conditions of the Quality Agreement (“Non-Conforming Material”). Reka-Farm shall not
Deliver and Dermata shall not be required to accept Delivery of any Material that was Collected more than twelve (12) months prior to the Delivery Date, which Material shall automatically be deemed to be
Non-Conforming Material. Dermata will provide written notice of the acceptance of any Delivered Batch within thirty (30) days of a Batch arriving at Dermata’s contract manufacturing facility;
provided, however, Dermata may later reject, in whole or in part, any Delivered Batch if Dermata determines that such Batch, or any portion thereof, contained a latent defect that renders such Batch
Non-Conforming Material and shall provide Reka-Farm written notice of such later rejection and the basis therefor. 

5.3    In the event Reka-Farm disputes Dermata’s rejection of a Batch, or a portion thereof, as
Non-Conforming Material, Reka-Farm shall provide Dermata with written notice stating the basis for the dispute and the Parties shall work together in good faith to resolve such dispute. In the event the
Parties cannot otherwise reasonably resolve their dispute, the Parties shall submit a portion of such Pre-shipment Sample or Batch for independent testing in accordance with Section 5.3.1. 

5.3.1    Within ninety (90) days of Dermata receiving Reka-Farm’s written notice under Section 5.3, Dermata
shall submit samples from the Batches of disputed Non-Conforming Material to an independent testing laboratory or other appropriate expert selected by Dermata (the “Testing
Expert”) for Testing, as set forth in the Documentation. In the event the Testing Expert determines the disputed Batch, or portion thereof, meets the requirements of the Documentation, absent manifest error,

  
 12 

 
the findings of the Testing Expert shall be binding on the Parties and Dermata shall pay the costs of the Testing Expert and the Purchase Price for the disputed Batch or portion thereof. In the
event the Testing Expert determines the disputed Batch, or portion thereof, is Non-Conforming Material, Reka-Farm shall pay the costs of the Testing Expert and Dermata shall not be required to pay the Purchase
Price of the Non-Conforming Material and shall elect an option as stated in 5.3.2 below. 

5.3.2    In the event any Batch, or portion thereof, is finally determined to comprise
Non-Conforming Material, then at Dermata’s option, (a) Dermata may accept the Non-Conforming Material at the Purchase Price in the applicable Purchase Order
and have such Non-Conforming Material reprocessed to meet the Acceptance Criteria, with the cost of such reprocessing being borne solely by Reka-Farm and Reka-Farm reimbursing Dermata for such costs with
thirty (30) days of Reka-Farms’ receipt of an invoice from Dermata for such reprocessing costs, (b) Reka-Farm shall Deliver to Dermata within thirty (30) days the quantity of conforming Material set forth in the applicable
Accepted Purchase Order, or (c) in the event Dermata has already paid the Purchase Price for a quantity of Non-Conforming Material, then, at Dermata’s sole option, (i) Reka-Farm shall reimburse
Dermata, within thirty (30) days for the amount paid by Dermata with respect to such Non-Conforming Material, or (ii) Reka-Farm shall credit Dermata the Purchase Price paid for the Non-Conforming Material and such credit shall be applied to the next Batch to be delivered by Reka-Farm to Dermata pursuant to a subsequent Accepted Purchase Order. In addition to (a), (b) or (c) above,
Reka-Farm promptly shall reimburse Dermata for all costs incurred by Dermata with respect to such Non-Conforming Material (including all testing, shipping, handling and other transportation costs, duties,
fees, levies and taxes). Dermata shall have the right to offset any such costs against any payments owed by Dermata to Reka-Farm under this Agreement. 

5.3.3    Reka-Farm shall immediately notify Dermata if at any time it discovers that any Batch, or any portion of any
Batch, intended for Delivery to Dermata hereunder contains any Non-Conforming Material. 

5.4    Return of Material. In the event that Dermata has taken possession of a Batch of Material that is determined to be Non-Conforming Material and Dermata elects not to reprocess such Non-Conforming Material in accordance with Section 5.3.2(a) above, it shall, at Reka-Farm’s option,
(i) destroy such Non-Conforming Material, at Reka-Farm’s expense, or (ii) ship such Non-Conforming Material, at Reka-Farm’s expense, to a location
specified by Reka-Farm. Notwithstanding the foregoing, and in the event Reka-Farm does not provide instructions to Dermata regarding shipment or disposal of Non-Conforming Material within sixty (60) days
following the date of Dermata’s written notice to Reka-Farm requesting such instructions, Dermata shall be permitted to dispose of such Non-Conforming Material in a method of its choosing and Reka-Farm
shall reimburse Dermata for the costs of such disposal. 
 5.5    Recalls. Dermata shall be solely responsible for activities
relating to a recall or withdrawal of a Products (“Recall”), including all communications with Regulatory Authorities relating to such a Recall. Reka-Farm shall cooperate with and give all reasonable assistance to Dermata in
conducting any such Recall to the extent it relates to a Products. If a Recall results from (a) Reka-Farm breaching any Applicable Laws, the terms and conditions of this Agreement or the Quality Agreement, (b) Reka-Farm providing Material
not in conformance with the Documentation, or (c) as a result of Reka-Farm’s negligence or willful misconduct in conducting its activities under this Agreement, then Reka-Farm shall (i) bear the actual and reasonable expenses of
Dermata in carrying out such Recall, and (ii) use its best efforts to promptly replace the Material subject to such Recall with conforming Material at Reka-Farm’s expense. 

  
 13 

 ARTICLE VI. 

REPRESENTATIONS AND WARRANTY 

6.1    Representations and Warranties. In connection with this Agreement and each Delivery of Material to Dermata hereunder,
Reka-Farm hereby represents and warrants to Dermata that, as of this Agreement and as of each relevant Delivery Date of such Material to Dermata: 

(a)    such Material is in conformity with the Applicable Laws, Documentation and Acceptance Criteria and the applicable
Certificate of Analysis, unless otherwise agreed in writing by the Parties; 
 (b)    all activities associated with
Collecting, Processing, Testing and Supplying under this Agreement have been and will be conducted in conformance with all Applicable Laws, and the terms and conditions of this Agreement and the Quality Agreement; 

(c)    title to such Material will pass to Dermata free and clear of any security interest, lien or other encumbrance;
Reka-Farm has full title and right to such Material under Applicable Laws. 
 (d)    such Material has been Tested at
the Testing Facility and those portions of the Testing Facility used in the Testing of the Material were in compliance with all Applicable Laws at the time Testing took place; 

(e)    the expiration date of such Material (provided it is stored in accordance with Reka-Farm’s instructions) is no
earlier than [***] after the Collection Date thereof (or such longer period after the Collection Date thereof as may be mutually agreed upon in writing by the Parties and supported by ongoing stability studies); and 

(f)    neither Reka-Farm nor any of its Affiliates has been debarred or is subject to debarment pursuant to 21 U.S.C.
§ 335(a) or (b) or any similar law in any country. 
 6.2    Licenses and Permits. Reka-Farm hereby represents and
warrants to Dermata that Reka-Farm has, at the time of each Delivery, all necessary licenses, permits or approvals required by Applicable Laws in connection with such Delivery and shall obtain and maintain throughout the Term all necessary licenses,
permits or approvals required by Applicable Laws in connection with the Collecting and Processing of Spongilla and the Testing and Supply of Material, including, without limitation, permits related to its Facilities. 

6.3    Material Supply. Reka-Farm hereby covenants that it shall maintain sufficient Facilities, relationships, rights, personnel
and resources to meet its obligations under this Agreement to supply the quantities of Material specified in an Accepted Purchase Order. 

6.4    Infringement. Reka-Farm hereby represents and warrants that as of the Effective Date it is not aware that the supply of
Material or its process for Processing the Material as conducted prior to the Effective Date, and as proposed to by Reka-Farm to be conducted following the Effective Date, infringes, misappropriates or violates any patent, trade secret or other
Intellectual Property Rights of any Third Party. 
 6.5    Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS
AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO THE MATERIAL, AND HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NON-INFRINGEMENT 

  
 14 

 
WITH RESPECT TO THE MATERIAL. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, COLLECTION, PROCESSING AND SUPPLY OR COMMERCIALIZATION OF THE PRODUCTS PURSUANT TO
THIS AGREEMENT WILL BE SUCCESSFUL. 
 ARTICLE VII. 

CONFIDENTIALITY 

7.1    Confidentiality. “Confidential Information” means all non-public,
confidential, or proprietary information of a Party, or its Affiliates, whether in oral, written, electronic, or other form or media, whether or not such information is marked, designated, or otherwise identified as “confidential” and
includes the terms of this Agreement and any information that, due to the nature of its subject matter or circumstances surrounding its disclosure, would reasonably be understood to be confidential or proprietary, including, specifically: (a) a
Party’s other unpatented inventions, ideas, methods, discoveries, know-how, trade secrets, unpublished patent applications, invention disclosures, invention summaries, and other confidential intellectual
property; (b) all other business, financial or technical information, designs, specifications, documentation, components, source code, object code, images, icons, audiovisual components and objects, schematics, drawings, protocols, processes,
and other visual depictions, in whole or in part, of any of the foregoing; and (c) all notes, analyses, compilations, reports, forecasts, studies, samples, data, statistics, summaries, interpretations, and other materials prepared by or for a
Party, its Affiliates or its Representatives (as defined below) that contain, are based on, or otherwise reflect or are derived from any of the foregoing in whole or in part. 

Confidential Information shall not include information which: 

7.1.1    prior to receipt thereof from one Party was in the possession of the receiving Party and at its free disposal, as
can be demonstrated by the receiving Party through written evidence; 
 7.1.2    is subsequently disclosed to the
receiving Party without any obligations of confidence by a Third Party who has not derived it directly or indirectly from the disclosing Party; 

7.1.3    is or becomes generally available to the public through no act or default of the receiving Party or its
Representatives, or Affiliates; 
 7.1.4    is independently developed by the receiving Party without the benefit of any
disclosure hereunder, as demonstrated by documented evidence prepared contemporaneously with such independent development; or 

7.1.5    is required to be disclosed by law, regulation or action of any governmental agency or authority or to comply
with the requirements of any securities exchange or to any governmental or regulatory agency, including any Regulatory Authority, in connection with a regulatory filing. 

No Confidential Information is included in any of the foregoing exceptions merely because it comprises or relates to the same general subject
matter as a specific item of disclosure falling within such exceptions, nor is any general subject matter of Confidential Information within any of the foregoing exceptions merely because one or more specific items comprising or relating to such
subject matter fall within such exceptions. 
 7.2    Dermata agrees to maintain secret and confidential the Confidential Information
that it may acquire, or has acquired, from Reka-Farm during the Term of this Agreement (“Reka-Farm Confidential 

  
 15 

 
Information”), to use the same exclusively as permitted under this Agreement, and to disclose the same only to those of its employees, advisors, agents, contractors
(“Representatives”), and Affiliates to whom and to the extent that such disclosure is reasonably necessary for the purposes of this Agreement. 

7.3    Reka-Farm agrees to maintain secret and confidential all Confidential Information that it may acquire, or has acquired, from
Dermata during the Term (“Dermata Confidential Information”), to use the same exclusively as permitted under this Agreement, and to disclose the same only to those of its Representatives, and Affiliates to whom and to the extent
that such disclosure is reasonably necessary to fulfill its obligations under this Agreement. 
 7.4    Notwithstanding the foregoing
provisions of the Article 7, Confidential Information provided under this Agreement may be disclosed to Representatives, and Affiliates of the receiving Party, but only to the extent permitted or required to accomplish the purposes of this
Agreement; provided that such Representatives, Affiliates, shall also agree to appropriate and comparable confidentiality and non-use provisions. The receiving Party shall be responsible for any
breaches of this Agreement by its Representatives, or Affiliates. In addition, a Party may disclose information provided under this Agreement by the other Party to any Regulatory Authority to obtain approval to market a Products, but such disclosure
may be made only to the extent necessary to obtain such approval. A Party may disclose information provided by the other Party as reasonably necessary in connection with the due diligence process associated with future capital investments or
financings or the negotiation or exploration of possible strategic transactions, sublicenses or acquisitions, subject to customary confidentiality agreements with the applicable Third Party(ies). 

7.5    The obligations of confidentiality herein shall survive without limit in time, shall apply to Reka-Farm Confidential Information
and Dermata Confidential Information exchanged between the Parties, both prior to and after entering into this Agreement and, with respect to such information, replace any and all previous confidentiality obligations owed by either Party to the
other relating to the subject matter of this Agreement and the Material (including, without limitation, under the Non-Disclosure Agreement executed by the Parties on December 12, 2017). 

7.6    Upon the termination of this Agreement, all Confidential Information of the disclosing Party in the receiving Party’s
possession will be returned to the disclosing Party (or destroyed by the receiving Party, with written confirmation of such destruction), and the receiving Party will make no further use thereof. Notwithstanding the foregoing, the receiving Party
may retain copies of the disclosing Party’s Confidential Information to the extent required to be kept (a) pursuant to any legal and/or regulatory requirement, (b) for compliance with any internal document retention or corporate
governance policy or (c) in the receiving Party’s secure electronic archives or backup systems. Any of the disclosing Party’s Confidential Information so retained shall continue to remain subject to the provisions of this Agreement.

 7.7    Publications and Publicity. Dermata shall have the right to publish and/or publicly present any information and data
relating to the Products and/or the Supply of Material, including any Reka-Farm Confidential Information. Except as required by Applicable Laws or court order, all publicity, press releases and other public announcements or disclosures relating to
the existence and terms of this Agreement or the transactions contemplated hereby by Reka-Farm shall be reviewed in advance by, and shall be subject to the prior written approval of Dermata. In addition, the Parties hereby agree that:
(a) Dermata may issue a press release or public announcement concerning any aspect of Dermata’s development or commercialization of a Products, including related to the existence and terms of this Agreement or the transactions contemplated
hereby, (b) both Parties may disclose the existence of this Agreement and the terms and conditions hereof, without the prior written consent of the other Party, as may be required by Applicable Laws (including, without limitation, disclosure
requirements of the United States Securities and Exchange Commission, the New York Stock Exchange, NASDAQ, or any other exchange or foreign 

  
 16 

 
counterparts thereof); provided, that each Party shall give the other Party reasonable advance notice and an opportunity to review any such disclosure, and (c) Dermata may disclose
the existence of this Agreement and the terms and conditions hereof, without the prior written consent of Reka-Farm, as reasonably necessary in connection with the due diligence process associated with future capital investment or the negotiation or
exploration of possible financings, strategic transactions, sublicenses or acquisitions, subject to customary confidentiality agreements with the applicable Third Party(ies). 

ARTICLE VIII. 

INTELLECTUAL PROPERTY 

8.1    Ownership of Dermata Intellectual Property Rights. Dermata shall solely own or control any Intellectual Property Rights that
were owned or controlled by Dermata prior to the Effective Date (“Dermata Intellectual Property Rights”). 

8.2    Ownership of Reka-Farm Intellectual Property Rights. Reka-Farm shall solely own or control any Intellectual Property Rights
that were owned or controlled by Reka-Farm prior to the Effective Date and outside the scope of this Agreement (“Reka-Farm Intellectual Property Rights”). 

8.3    Ownership of Deliverables and Intellectual Property Rights in Deliverables. Dermata is, and shall be, the sole and exclusive
owner of all right, title and interest in and to all documents, data, information, work product and other materials, and all Intellectual Property Rights therein, that are delivered to Dermata (“Deliverables”) by Reka-Farm as a
result of Reka-Farm conducting activities pursuant to this Agreement. Any Intellectual Property Rights in Deliverables shall be deemed Dermata Intellectual Property Rights and the contents of Deliverables shall be deemed Dermata Confidential
Information. Reka-Farm hereby irrevocably assigns, and shall cause Reka-Farm personnel to irrevocably assign to Dermata, in each case without additional consideration, all right, title and interest throughout the world in and to the Deliverables,
including all Intellectual Property Rights in Deliverables. Reka-Farm shall cause Reka-Farm personnel to irrevocably waive, to the extent permitted by Applicable Laws, any and all claims such Reka-Farm personnel may now or hereafter have in any
jurisdiction to so-called “moral rights” or rights of droit moral with respect to the Deliverables. Upon the request of Dermata, Reka-Farm shall, and shall cause Reka-Farm Personnel to, promptly take
such further actions, including execution and delivery of all appropriate instruments of conveyance, as may be necessary to assist Dermata to prosecute, register, perfect or record its rights in or to any Deliverables. Reka-Farm shall cause
Reka-Farm Contactors to assign to Dermata or Reka-Farm, as applicable, to assign to Dermata, in each case without additional consideration, all right, title and interest throughout the world each such Reka-Farm Contractor may have in and to the
Deliverables, including all Intellectual Property Rights in Deliverables. Reka-Farm shall also cause Reka-Farm Contactors to irrevocably waive, to the extent permitted by Applicable Laws, any and all claims such Reka-Farm personnel may now or
hereafter have in any jurisdiction to so-called “moral rights” or rights of droit moral with respect to the Deliverables. 

8.4    Ownership of Know-How and Developments. During the course of this Agreement, the
Parties may, solely or jointly, generate inventions, improvements, discoveries, methods, novel information or other valuable know-how (“Know-How”). In
order to permit and encourage a successful collaboration and protect the key business interests of both Parties, the Parties agree that all Know-How conceived, generated, derived or first reduced to practice
by Reka-Farm as a result of services performed under this Agreement or related to the Materials (“Developments”), and all Intellectual Property Rights therein, are and shall be the exclusive property of Dermata, to the extent not
prohibited by Applicable Laws. All Intellectual 

  
 17 

 
Property Rights in Know-How and Developments shall be deemed Dermata Intellectual Property Rights, and the content of such
Know-How and Developments shall be deemed the Dermata Confidential Information. Reka-Farm agrees to assign its rights in all such Developments and Know-How, including
all Intellectual Property rights in Know-How and Developments to Dermata without further consideration and from the time when the relevant Know-How or Developments were
generated. Reka-Farm shall cause Reka-Farm Personnel to irrevocably waive, to the extent permitted by Applicable Laws, any and all claims such Reka-Farm Personnel may now or hereafter have in any jurisdiction to any rights with respect to the Know-How and Developments and shall not register any such rights. Upon the request of Dermata, Reka-Farm shall, and shall cause Personnel to, promptly take such further actions, including execution and delivery of
all appropriate instruments of conveyance, as may be necessary to assist Dermata to prosecute, register, perfect or record the rights of Dermata in or to any Intellectual Property Rights, Know-How or
Developments. Reka-Farm shall cause Reka-Farm Contactors to assign to Dermata or Reka-Farm, as applicable, to assign to Dermata, in each case without additional consideration, all right, title and interest throughout the world (including in the
Russian Federation) each such Reka-Farm Contractor may have in and to Know-How and Developments, including all Intellectual Property Rights in Know-How and Developments.
Reka-Farm shall also cause Reka-Farm Contactors to irrevocably waive, to the extent permitted by Applicable Laws, any and all claims such Reka-Farm personnel may now or hereafter have in any jurisdiction to
so-called “moral rights” or rights of droit moral with respect to Know-How and Developments. 

8.5    Grant of License by Dermata to Reka-Farm under Dermata Intellectual Property Rights. Dermata hereby grants to Reka-Farm
during the Term a non-exclusive, limited, non-assignable, sublicensable (but only in accordance with this Section 8.5), royalty-free license within the Territory
under the Dermata Intellectual Property Rights solely for the purpose of fulfilling Reka-Farm’s obligations to Dermata under this Agreement. The license granted to Reka-Farm in this Section 8.5 is sublicensable by Reka-Farm only to
Reka-Farm Contractors, and only for the period during which such Reka-Farm Contractors are providing services on behalf or Reka-Farm under this Agreement, and only for the limited purpose of fulfilling Reka-Farm’s obligations to Dermata under
this Agreement. 
 8.6    Grant of License by Reka-Farm to Dermata under Reka-Farm Intellectual Property Rights. Reka-Farm hereby
grants to Dermata during the Term an exclusive, royalty-bearing, sublicensable license in the Territory under Reka-Farm Intellectual Property Rights for the purpose of making, using, selling, offering for sale, and importing Spongilla, Material and
Products. Reka-Farm further grants to Dermata during the Term a non-exclusive, royalty-free, sublicensable license outside the Territory under Reka-Farm Intellectual Property Rights for the purpose of
developing, testing making, having made, using, selling, offering for sale, and importing Spongilla, Material and Products in the Territory. 

8.7    Reka-Farm will not knowingly utilize any technology owned or controlled by any Third Party, including any technology subject to
Third-Party Intellectual Property Rights, for the purposes of Collecting, Processing, Testing and Supplying Material without first providing Dermata with written notice thereof, and agreeing upon terms for the use of such technology. 

8.8    Except as expressly set forth in this Agreement, neither Party shall acquire or register any license, express or implied, to any
Intellectual Property Rights of the other Party pursuant to this Agreement, nor do the Parties intend that any agency or partnership relationship be created by this Agreement. Each Party is and shall remain the exclusive owner of its Confidential
Information and all Intellectual Property Rights therein. 

  
 18 

 8.9    Notwithstanding any other provision of this Agreement, neither Reka-Farm nor any
of its Affiliates, Reka-Farm Contractors or other permitted Reka-Farm sublicensees shall have any right or license to use any Dermata Trademarks, and any such use by Reka-Farm, its Affiliates, Reka-Farm Contractors or other permitted Reka-Farm
sublicensees shall be considered a material breach of this Agreement by Reka-Farm. 
 ARTICLE IX. 

INSURANCE AND INDEMNIFICATION 

9.1    Reka-Farm Insurance. Reka-Farm shall maintain commercial general liability insurance and product liability insurance with a
minimum limit per occurrence of $1,000,000 prior to first human use of a Products containing Material supplied hereunder and $10,000,000 per occurrence following such first human use. Upon Dermata’s request, Reka-Farm will name Dermata as an
additional-insured on such insurance policies and will provide to Dermata copies of certificates of insurance verifying such coverage. 

9.2    Dermata Insurance. Dermata and its Affiliates shall maintain commercial general liability insurance and product liability
insurance with a minimum limit of $1,000,000 per occurrence prior to first human use of the Products, and $5,000,000 per occurrence following such first human use. Upon request, Dermata will provide to Reka-Farm copies of certificates of insurance
verifying such coverage. 
 9.3    Indemnification by Reka-Farm. Reka-Farm shall indemnify and hold harmless Dermata and its
Affiliates, and each of their respective employees, officers, directors and agents (each a “Dermata Indemnitee”) from and against (i) any and all liabilities, losses and damages (“Losses”) finally awarded to a
Third Party by a court of competent jurisdiction that result from any charge, allegation, notice, civil, criminal, employment or administrative claim, demand, complaint, cause of action, suit, proceeding, arbitration, hearing or investigation (each
a “Claim”) made or brought against a Dermata Indemnitee by or on behalf of such Third Party, and (ii) subject to Section 9.5, any direct
out-of-pocket costs and expenses (including reasonable attorneys’ fees) (“Litigation Costs”) incurred by a Dermata Indemnitee while investigating
or conducting the defense of such Third Party Claim, in any such case (i) and (ii), solely to the extent such Claim is directly based on or directly arises out of the breach by Reka-Farm of any representation, warranty or covenant contained in
this Agreement; provided, however, that such indemnification right shall not apply to any Claims, Losses or Litigation Costs (x) to the extent directly attributable to the gross negligence, reckless misconduct, or intentional misconduct
of a Dermata Indemnitee, or (y) for which Dermata is obligated to indemnify Reka-Farm under Section 9.4. 

9.4    Indemnification by Dermata. Dermata shall indemnify and hold harmless Reka-Farm and its Affiliates and each of their
respective employees, officers, directors and agents (each a “Reka-Farm Indemnitee”) from and against (i) any and all Losses finally awarded to a Third Party by a court of competent jurisdiction that result from any Claim made
or bought against a Reka-Farm Indemnitee by or on behalf of such Third Party, and (ii) subject to Section 9.5, any Litigation Costs incurred by a Reka-Farm Indemnitee while investigating or conducting the defense of such Third Party Claim,
in any such case solely to the extent such Claim is directly based on or directly arises out of the breach by Dermata of any representation, warranty or covenant contained in this Agreement; provided, however, that such indemnification right
shall not apply to any Claims, liability, loss, damage, cost and expense (x) to the extent directly attributable to the negligence, reckless misconduct, or intentional misconduct of a Reka-Farm Indemnitee or Reka-Farm’s breach of this
Agreement, or (y) for which Reka-Farm is obligated to indemnify Dermata under Section 9.3. 
 9.5    Indemnification
Procedures. Promptly after receipt by a Party seeking indemnification under this 

  
 19 

 
Section 9 (an “Indemnitee”) of notice of any pending or threatened Claim against it, such Indemnitee shall give written notice thereof to the Party from whom the Indemnitee
is entitled to seek indemnification pursuant to this Section 9 (the “Indemnifying Party”); provided, that the failure so to notify the Indemnifying Party shall not relieve it of any liability that it may have to any
Indemnitee hereunder, except to the extent the Indemnifying Party demonstrates that it is materially prejudiced thereby. The Indemnifying Party shall be entitled to participate in the defense of such Claim and, to the extent that it elects within
seven (7) days of its receipt of notice of the Claim from the Indemnitee, to assume control of the defense of such Claim (unless (i) the Indemnifying Party is also a party to such proceeding and the Indemnifying Party has asserted a cross
claim against the Indemnitee or a court has otherwise determined that such that joint representation would be inappropriate, or (ii) the Indemnifying Party fails to provide reasonable assurance to the Indemnitee of its financial capacity to
defend the Indemnitee in such proceeding) with counsel reasonably satisfactory to the Indemnitee and, after notice from the Indemnifying Party to the Indemnitee of its election to assume the defense of such Claim, the Indemnifying Party shall not,
as long as it diligently conducts such defense, be liable to the Indemnitee for any Litigation Costs subsequently incurred by the Indemnitee. The Indemnitee shall provide the Indemnifying Party with such information and assistance as the
Indemnifying Party may reasonably request with regard to the Claim. No compromise or settlement of any Claim may be effected by the Indemnifying Party without the Indemnitee’s written consent, which consent shall not be unreasonably withheld or
delayed, unless (a) there is no finding or admission of any violation of Applicable Laws or any violation of the rights of any person and no effect on any other claims that may be made against the Indemnitee, (b) the sole relief provided
is monetary damages that are paid in full by the Indemnifying Party, and (c) the Indemnitee’s rights under this Agreement are not restricted by such compromise or settlement. 

ARTICLE X. 
 TERM;
TERMINATION 
 10.1    Term. The term of this Agreement shall commence on the Effective Date and, shall survive in full
force indefinitely unless terminated as hereinafter provided in this Article X (the “Term”). 
 10.2    Termination
of Agreement for Breach. Either Party may terminate this Agreement and the License for material breach of this Agreement by the other Party by giving ninety (90) days’ written notice to the breaching Party, (specifying in reasonable
detail the basis for such termination) and such breaching Party has not cured such breach within such period. 
 10.3    Termination
of Agreement by Dermata. Dermata may terminate this Agreement upon not less than ninety (90) days written notice to Reka-Farm for any reason or no reason (i) in whole, or (ii) in any specific country in the Territory. 

10.4    Consequences of Termination. In the event Dermata terminates this Agreement under this Article X, the licenses granted by
Dermata to Reka-Farm under Section 8.5 shall terminate in whole upon the date of the termination of the Agreement. 

10.5    Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to
such expiration or termination. Any termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to termination, including without limitation, commitments
under binding orders for Material. The provisions of Sections 3.5, 3.8, 4.2, 4.3, 4.4, 4.5, 4.6, 5.4, 5.5, 6.1, 12.1, 12.10 and this 10.5 and Articles 1, 7, 8 and 9 shall survive any termination of this Agreement. 

  
 20 

 ARTICLE XI. 

DISPUTE RESOLUTION 

11.1    Informal Resolution. Subject to Section 12.5, in the event of any controversy, dispute or claim arising out of,
in connection with, or in relation to the interpretation, performance, or alleged breach of this Agreement (the “Dispute”), prior to instituting any arbitration on account of such Dispute, the Parties shall attempt in good faith to
settle such Dispute first by negotiation and consultation between themselves, including referral of such Dispute to the Chief Executive Officer of Dermata and the Director General of Reka-Farm. In the event said executives are unable to resolve such
Dispute or agree upon a mechanism to resolve such Dispute within thirty (30) days of the first written request for dispute resolution under this Section 11.1, then the Parties shall resolve all such Disputes in accordance with
Section 11.2. 
 11.2    Arbitration. If any Dispute has not been resolved by good faith negotiations between the
Parties pursuant to Section 11.1 above, then any such Dispute, controversy or claim which may arise out of or in connection with this Agreement or the execution, breach, termination or invalidity thereof, shall be submitted to the International
Court of Arbitration of the International Chamber of Commerce and shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators appointed in accordance with such rules. The arbitral award
shall be final for the Parties. Submission to the state court of an application for making a decision in the absence of competence of the arbitral tribunal in connection with the issuance of a separate award as a decision on a preliminary question
of the competence of the arbitral tribunal is prohibited. 
 ARTICLE XII. 

MISCELLANEOUS 

12.1    Governing Law. This Agreement shall be governed by the laws of the State of California, United States of America, without
regard to its conflict of law provisions. The Parties agree that the United Nations Convention on Contracts for the International Sale of Goods does not apply to this Agreement. 

12.2    Unenforceability. Both Parties hereby expressly state that it is not the intention of either Party to violate any
Applicable Laws. If any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions which will achieve as far as possible the economic
business intentions of the Parties. 
 12.3    Compliance with Law. Reka-Farm shall comply with and shall use Commercially
Reasonable Efforts to ensure that its Affiliates and Representatives comply with all Applicable Laws in carrying out its rights and obligations under this Agreement. Dermata shall comply with and shall use Commercially Reasonable Efforts to ensure
that its Affiliates and Representatives comply with all laws, regulations, rules, guidelines and regulations applicable to the conduct of its business within the United States, as well as the GACP. 

12.4    FCPA Compliance. Reka-Farm represents and warrants that Reka-Farm is familiar with all applicable anti-corruption and
anti-bribery laws, including the U.S. Foreign Corrupt Practices Act (“FCPA”), and all applicable anti-corruption and anti-bribery laws and regulations in effect in the countries in which Reka-Farm conducts or will conduct business,
including those set out under Applicable Laws. Reka-Farm agrees that in the course of its performance under this Agreement, it will not, either directly or through an intermediary, give or offer to give anything of value to a government official (or
candidate for 

  
 21 

 
government office), an official of a public international organization, or a political party or party official, for purposes of influencing the official’s decisions, inducing the official to
do or omit doing some act, or securing any improper advantage. Any breach of the foregoing obligation shall constitute a material breach of this Agreement and shall entitle Dermata to exercise all available remedies hereunder at law or equity. Such
a breach shall also entitle Dermata to the return of all amounts paid to Reka-Farm hereunder by or on behalf of Dermata. 

12.5    Injunctive Relief. Reka-Farm and Dermata agree that if certain material obligations under this Agreement are not performed
in accordance with their specific terms or are otherwise breached, (a) severe and irreparable damage would occur, (b) no adequate remedy at law would exist, and (c) damages would be difficult to determine. Reka-Farm and Dermata agrees
that, in such case, the injured Party shall be authorized and entitled to seek to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, as well as any other relief permitted by applicable law, and the
breaching Party shall waive any requirement that such Party post bond as a condition for obtaining any such relief. 
 12.6    No
Waiver. The failure by either Party to take any action or assert any right hereunder shall in no way be construed to be a waiver of such right, nor in any way be deemed to affect the validity of this Agreement or any part hereof, or the right of
a Party to thereafter enforce each and every provision of this Agreement. 
 12.7    Drafting. This Agreement shall not be
construed more strictly against one Party than the other because it may have been drafted by one of the Parties or its counsel, the Parties having contributed through its counsel substantially and materially to the negotiation and drafting thereof.

 12.8    Assignment. This Agreement and the Parties’ rights and obligations hereunder shall not be assignable except with
the prior written consent of the other Party, not to be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, Dermata shall have the right to assign this Agreement or its rights or obligations under this Agreement without
Reka-Farm’s prior written consent to any of its Affiliates, successors in interest or acquirors of all or substantially all of its assets, including any successor in interest by way of any reincorporation or other reorganization;
provided, that such Affiliate, successor in interest or acquirer assumes all Dermata’s obligations under this Agreement. 

12.9    Relationship of the Parties. In making and performing this Agreement, the Parties are acting, and intend to be treated, as
independent entities and nothing contained in this Agreement shall be construed or implied to create an agency, partnership, joint venture, or employer and employee relationship between or among any of the Parties. Except as otherwise provided
herein, no Party may make any representation, warranty or commitment, whether express or implied, on behalf of or incur any charges or expenses for or in the name of any other Party. No Party shall be liable for the act of any other Party unless
such act is expressly authorized in writing by such Party. 
 12.10    Notices. Every notice, election, demand, consent, request,
approval, report, offer, acceptance, certificate, or other communication required or permitted under this Agreement or by Applicable Laws shall be in writing and shall be deemed to have been delivered and received (a) when delivered in person
or by courier or electronic mail (with confirmation sent by another method herein) (b) upon confirmation of receipt when sent by certified mail, return receipt requested; or (c) upon receipt when sent by reputable private international
courier with established tracking capability (such as DHL, FedEx, or UPS), postage paid and addressed as set forth as the case may be, to the noticed, Reka-Farm or Dermata, at the address set forth below, or such other address as Reka-Farm or
Dermata may specify by written notice to the other. 
 For Reka-Farm: 

Reka-Farm 

  
 22 

 [***] 

For Dermata: 
 Dermata
Therapeutics, LLC. 
 3525 Del Mar Heights Rd., #322 

San Diego, CA 92130 
 Attn: Chief
Executive Officer 
 12.11    Force Majeure. If and to the extent that either Party is prevented or delayed by a Force Majeure
Event from performing any of its obligations under this Agreement and promptly so notifies the other Party, specifying the matters constituting the Force Majeure Event, together with such evidence in verification thereof as it can reasonably give
and specifying the period for which it is estimated that the prevention or delay will continue, then the Party so affected shall be relieved of liability to the other for failure to perform or for delay in performing such obligations (as the case
may be), but shall nevertheless use its best endeavors to resume full performance thereof; provided, however, that if the Force Majeure Event continues for a period of ninety (90) days or more following notification, the Party not
affected by the Force Majeure Event may terminate this Agreement by giving not less than thirty (30) days prior notice to the other Party. 

12.12    Headings. The captions to the Sections hereof are not a part of this Agreement, but are merely guides or labels to assist
in locating and reading the several Sections hereof. 
 12.13    Set Off. Dermata shall have a right to set-off any amounts due under this Agreement to Reka-Farm and/or Mikhail Petrovichev against any damages incurred by Dermata and/or its Affiliates (solely as demonstrated by a final, unappealable judgment against
Reka-Farm with respect to such damages) due to any material breach of this Agreement by Reka-Farm, its Affiliates or Mikhail Petrovichev. In the event such set-off is insufficient to satisfy such judgment, any
portion thereof which is not satisfied, shall bear interest equal to one percent (1%) per month calculated on the number of days such payment is delinquent and compounded monthly until satisfied by further
set-off or payment. 
 12.14    Counterparts. This Agreement, and any amendment or
supplement hereto, may be executed in any number of counterparts, and any Party hereto may execute any such counterpart, each of which when executed and delivered shall be deemed to be an original and all of which counterparts taken together shall
constitute but one and the same instrument. The execution of this Agreement and any such amendment or supplement by any Party hereto will not become effective until counterparts hereof have been executed by both Parties hereto. 

[REMAINDER OF PAGE LEFT BLANK INTENTIONALLY] 

  
 23 

 IN WITNESS WHEREOF, the Parties have caused this Supply Agreement to be executed by their respective
duly authorized representatives as of the day and year first above written. 
  

					
	DERMATA THERAPEUTICS, LLC	 		 	REKA-FARM, LLC.
			
	By: /s/ Gerald T. Proehl                               
                             	 		 	By: /s/ Mikhail Petrovichev                             
                       
			
	Name: Gerald T. Proehl	 		 	Name: Mikhail Petrovichev
			
	Title: President and CEO	 		 	Title: Director General

  

					
		 		 	MIKHAIL PETROVICHEV
			
		 		 	By: /s/ Mikhail Petrovichev                             
                        
			
		 		 	Name: Mikhail Petrovichev
			
		 		 	Title: Individual

  
 24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]